KRRO — FREQUENCY THERAPEUTICS INC (Healthcare >> Biotechnology)
KRRO FAQ
What is KRRO's ROE?
FREQUENCY THERAPEUTICS INC reports a Return on Equity (ROE) of -94.87%.
What is KRRO's dividend yield?
FREQUENCY THERAPEUTICS INC offers a dividend yield of 0.00%.
What is KRRO's Deepscope Quality Score?
Deepscope rates KRRO's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KRRO?
Deepscope's AI Timing Score for KRRO is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KRRO belong to?
FREQUENCY THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 10.59
Price
-0.13
(-1.21%)
Day Change
|
|
|---|
KRRO, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 10.59 |
| PBV / Sector |
1.29 / 4.75
GOOD
|
| Earning Per Share | -7.77 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
1.56 M
GREAT
|
| Average 1W Daily Value |
1.51 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-09 09:40:02 |
| Symbol | KRRO |
| Name | FREQUENCY THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 14.42 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 154.61 / 9,000.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 60 First Street, Cambridge, MA, United States, 02141
Phone: 617 468 1999
Website: https://www.korrobio.com
Sector: Healthcare >> Biotechnology
Description: Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google